Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11805389rdf:typepubmed:Citationlld:pubmed
pubmed-article:11805389lifeskim:mentionsumls-concept:C0005794lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0357131lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0870186lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C1879316lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0030703lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C1555471lld:lifeskim
pubmed-article:11805389lifeskim:mentionsumls-concept:C0439608lld:lifeskim
pubmed-article:11805389pubmed:issue5-6lld:pubmed
pubmed-article:11805389pubmed:dateCreated2002-1-23lld:pubmed
pubmed-article:11805389pubmed:abstractTextThis randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3-4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation.lld:pubmed
pubmed-article:11805389pubmed:languageenglld:pubmed
pubmed-article:11805389pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:citationSubsetIMlld:pubmed
pubmed-article:11805389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11805389pubmed:statusMEDLINElld:pubmed
pubmed-article:11805389pubmed:issn0014-312Xlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:JosefssonGGlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:DahlbergGGlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:SchaubRRlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:WurnigCClld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:MilbrinkJJlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:HemonYYlld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:Collaborative...lld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:HamardCClld:pubmed
pubmed-article:11805389pubmed:authorpubmed-author:NoskeHHlld:pubmed
pubmed-article:11805389pubmed:copyrightInfoCopyright 2001 S. Karger AG, Basellld:pubmed
pubmed-article:11805389pubmed:issnTypePrintlld:pubmed
pubmed-article:11805389pubmed:volume33lld:pubmed
pubmed-article:11805389pubmed:ownerNLMlld:pubmed
pubmed-article:11805389pubmed:authorsCompleteYlld:pubmed
pubmed-article:11805389pubmed:pagination303-10lld:pubmed
pubmed-article:11805389pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:meshHeadingpubmed-meshheading:11805389...lld:pubmed
pubmed-article:11805389pubmed:articleTitleSubcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation.lld:pubmed
pubmed-article:11805389pubmed:affiliationDepartment of Orthopedic Surgery, University of Vienna, Austria. christian.wurnig@oss.atlld:pubmed
pubmed-article:11805389pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11805389pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11805389pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:11805389pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:11805389pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11805389lld:pubmed